UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS

Retina (Philadelphia, Pa.), 2019-08, Vol.39 (8), p.1435-1450

2019

Volltextzugriff (PDF)

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

European journal of cancer (1990), 2020-02, Vol.126, p.33-44

2020

Volltextzugriff (PDF)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

Cancer, 2020-02, Vol.126 (3), p.523-530

2020

Volltextzugriff (PDF)

Response to trametinib treatment in progressive pediatric low-grade glioma patients

Journal of neuro-oncology, 2020-09, Vol.149 (3), p.499-510

2020

Volltextzugriff (PDF)

How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma

European journal of cancer (1990), 2018-11, Vol.103, p.41-51

2018

Volltextzugriff (PDF)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Therapeutic Advances in Medical Oncology, 2015-03, Vol.7 (2), p.122-136

2015

Volltextzugriff (PDF)

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

BMC cancer, 2019-12, Vol.19 (1), p.1250-1250, Article 1250

2019

Volltextzugriff (PDF)

Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases

Glia, 2019-07, Vol.67 (7), p.1320-1332

2019

Volltextzugriff (PDF)

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel

Proceedings of the National Academy of Sciences - PNAS, 2020-07, Vol.117 (27), p.15846-15851

2020

Volltextzugriff (PDF)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

BMC cancer, 2017-08, Vol.17 (1), p.536-536, Article 536

2017

Volltextzugriff (PDF)

Granulomatous tattoo reaction associated with BRAF/MEK inhibitor therapy for metastatic melanoma

International journal of dermatology, 2024-11, Vol.63 (11), p.1630-1632

2024

Volltextzugriff (PDF)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

Therapeutic Advances in Medical Oncology, 2019-02, Vol.11, p.1758835919830826-1758835919830826

2019

Volltextzugriff (PDF)

The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors

International journal of cancer, 2018-01, Vol.142 (2), p.381-391

2018

Volltextzugriff (PDF)

Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors

Cancer, 2023-06, Vol.129 (12), p.1904-1918

2023

Volltextzugriff (PDF)

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

Cancer, 2017-06, Vol.123 (S11), p.2118-2129

2017

Volltextzugriff (PDF)

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

European journal of cancer (1990), 2020-05, Vol.130, p.219-227

2020

Volltextzugriff (PDF)

Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors

European journal of cancer (1990), 2024-01, Vol.197, p.113477-113477, Article 113477

2024

Volltextzugriff (PDF)

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study

European journal of cancer (1990), 2022-05, Vol.166, p.24-32

2022

Volltextzugriff (PDF)

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma

Journal of neuro-oncology, 2021-05, Vol.152 (3), p.515-522

2021

Volltextzugriff (PDF)

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

Molecular systems biology, 2017-01, Vol.13 (1), p.905-n/a

2017

Volltextzugriff (PDF)

Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series

Acta ophthalmologica (Oxford, England), 2024-06, Vol.102 (4), p.e651-e656

2024

Volltextzugriff (PDF)

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma

Cancer science, 2021-10, Vol.112 (10), p.4026-4036

2021

Volltextzugriff (PDF)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

Molecular oncology, 2020-08, Vol.14 (8), p.1833-1849

2020

Volltextzugriff (PDF)

Successful treatment of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy

Journal of dermatology, 2021-09, Vol.48 (9), p.1419-1422

2021

Volltextzugriff (PDF)

Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA‐DRB104

Journal of dermatology, 2024-06, Vol.51 (6), p.854-857

2024

Volltextzugriff (PDF)

1 – 25 von 2.968

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.794)
Mit Volltextzugriff
(2.641)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.628)
Life Sciences & Biomedicine
(2.472)
Humans
(1.640)
Mek Inhibitors
(1.439)
Oncology
(1.270)
Animals
(862)
Mutation
(853)
Melanoma
(847)
Kinases
(812)
Tumors
(675)
Mek Inhibitor
(592)
Signal Transduction
(556)
Cell Line, Tumor
(543)
Map Kinase
(532)
Mek
(512)
Cell Biology
(507)
Protein Kinase Inhibitors - Pharmacology
(495)
Apoptosis
(490)
Cancer
(482)
Female
(479)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.994)
EZB Electronic Journals Library
(1.670)
Ingenta E-Journals
(1.489)
Journals@Ovid
(1.030)
IngentaConnect Journals
(724)
Access via ScienceDirect (Elsevier)
(557)
Wiley Blackwell Single Titles
(455)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(414)
Springer journals
(406)
Wiley Online Library
(334)
Nature Journals
(308)
Publisher or Other Site
(298)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(244)
Nexis Uni
(206)
Access via Taylor & Francis
(181)
Taylor & Francis
(167)
Taylor & Francis Journals Complete
(121)
SAGE Journals
(57)
Ebook Central Perpetual and DDA
(49)
eBooks on EBSCOhost
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancers
(119)
Oncogene
(94)
European Journal Of Cancer
(68)
Plos One
(56)
International Journal Of Molecular Sciences
(50)
Febs Letters
(49)
Oncotarget
(47)
Scientific Reports
(44)
Biochemical And Biophysical Research Communications
(38)
Cancer Letters
(32)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(7)
... seit 90 Tagen
(26)

Menü

Weitere Dienste

Einstellungen

OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

Response to trametinib treatment in progressive pediatric low-grade glioma patients

How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Granulomatous tattoo reaction associated with BRAF/MEK inhibitor therapy for metastatic melanoma

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors

Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

Successful treatment of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy

Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA‐DRB104

Suchergebnisse filtern